Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- JRCS to Use Nucleic Acid Testing on Individual Samples of Donated Blood: PAFSC Committee
June 9, 2014
- MHLW Rejects Proposal to Abolish Market Expansion Re-Pricing Rule
June 6, 2014
- LDP Members with Vested Interests to Oppose Annual Drug Price Revision
June 6, 2014
- MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
- MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
- MHLW Orders Revision of Package Inserts to Urge Caution in Concurrent Use of ARBs and ACE Inhibitors
June 5, 2014
- MOF Budget Examiner Calls for Revising Price-Gap Rule for Key Premium
June 4, 2014
- MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
- Gov’t to Discuss Further Reforms of Mixed Care System, Commit to Deregulation: PM Abe
June 4, 2014
- “Difficult” to Include Annual NHI Price Revision in Govt Blueprint: Minister
June 4, 2014
- LDP Members Voice Mixed Opinions on Active Recommendation for HPV Vaccines
June 3, 2014
- TPP Talks over IP Rights Hitting Snag: Cabinet
June 3, 2014
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
- Government Panel Officially Proposes to Relax Current Mixed Care Rule
May 30, 2014
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Pharmaceuticals and Medical Devices Safety Information Calls for Proper Use of Schizophrenia Treatment Xeplion
May 29, 2014
- Integrated Guidelines Will Apply to “Research” Conducted by the Media as Well: MHLW
May 29, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…